News
-
A study published online in Pediatrics finds that children using a triamcinolone nasal spray for allergic rhinitis grew on average 0.44 cm/year less than children using a placebo nasal spray (5.65 cm/year compared to 6.09… Read more . . .
-
GlaxoSmithKline has announced that both the Arnuity Ellipta fluticasone furoate DPI and the Incruse Ellipta umeclidinium bromide DPI are now available in the US. Arnuity Ellipta was approved by the FDA in August 2014 for… Read more . . .
-
PARI has announced that following approval by the FDA, its eRapid nebulizer is now available for delivery of Pulmozyme dornase alfa inhalation solution for the treatment of cystic fibrosis. In Europe, the device, marketed as… Read more . . .
-
According to Alexza Pharmaceuticals, a Phase 2a study of AZ-002 Staccato alprazolam for the treatment of epilepsy patients with acute repetitive seizures has been initiated. The study will take place in-clinic, though AZ-002 is being… Read more . . .
-
Lupin Pharmaceuticals Coral Springs, FL R&D Center. Lupin Pharmaceuticals. is a specialty pharmaceutical company marketing generic and branded pharmaceutical products as well as Active Pharmaceutical Ingredients (APIs). Essential Duties and Responsibilities • Conduct standard and… Read more . . .
-
Boehringer Ingelheim has announced that the Spiriva Respimat tiotropium soft mist inhaler is now available in the United States. Patients will also still be able to purchase Spiriva Handihaler, the company said. The FDA approved… Read more . . .
-
According to Nexus6, a study conducted in New Zealand has shown that 84% of children using the Smartinhaler SmartTrack device, which provides both audio and visual reminders, used their inhalers as prescribed compared to 30%… Read more . . .
-
Inhalation Asia has announced that nicotine delivery, smoking cessation, and the treatment of tuberculosis will be among the topics addressed at IA15, to be held this September in Shenyang, China. Plenary speakers for the meeting… Read more . . .
-
NovaBiotics, which has plans to develop an inhaled version of its Lynovex cysteamine (NM001) for the treatment of cystic fibrosis, has announced that it has raised £5 million in a private placement from Woodford Investment… Read more . . .
-
Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK